Gossamer Bio, Inc. (NASDAQ:GOSS) Position Decreased by Victory Capital Management Inc.

Victory Capital Management Inc. decreased its holdings in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 3.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 265,407 shares of the company’s stock after selling 9,122 shares during the period. Victory Capital Management Inc. owned approximately 0.12% of Gossamer Bio worth $240,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its position in shares of Gossamer Bio by 1.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company’s stock worth $1,123,000 after purchasing an additional 13,902 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Gossamer Bio in the third quarter worth approximately $67,000. The Manufacturers Life Insurance Company lifted its position in shares of Gossamer Bio by 24.2% in the third quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock worth $380,000 after purchasing an additional 74,920 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of Gossamer Bio by 30.7% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock worth $1,862,000 after purchasing an additional 442,895 shares in the last quarter. Institutional investors own 81.23% of the company’s stock.

Wall Street Analysts Forecast Growth

GOSS has been the subject of a number of research analyst reports. Wedbush reissued an “outperform” rating and issued a $4.00 price target on shares of Gossamer Bio in a research report on Friday, March 14th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research report on Tuesday, March 18th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $9.20.

Gossamer Bio Trading Up 3.0 %

NASDAQ:GOSS opened at $1.39 on Friday. Gossamer Bio, Inc. has a 12 month low of $0.50 and a 12 month high of $1.55. The firm has a market cap of $315.84 million, a price-to-earnings ratio of -4.34 and a beta of 1.86. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The company’s 50 day moving average is $1.16 and its 200-day moving average is $0.98.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.15). The company had revenue of $9.38 million during the quarter, compared to analyst estimates of $7.02 million. Equities analysts anticipate that Gossamer Bio, Inc. will post -0.28 EPS for the current year.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.